Friday 15 May 2026
Night EditionRSS

ZOTPAPER

News without the noise

ZOTPAPER
Science

Researchers Find Popular IVF Hormone Add-On Has No Effect on Pregnancy Success

Study raises fresh concerns about unproven fertility treatments being marketed to vulnerable patients

edit
By LineZotpaper
Published
Read Time3 min
A hormone treatment commonly offered as an add-on to IVF cycles has been found to have no measurable impact on pregnancy success rates, according to new research, reigniting debate about the proliferation of costly and unproven fertility treatments being sold to hopeful patients.

A hormone-based treatment widely offered to IVF patients as a way to boost their chances of conception has been shown to be ineffective, researchers have found, raising serious questions about the regulation and marketing of so-called fertility add-ons.

The finding, reported by the Sydney Morning Herald, adds to a growing body of evidence that some supplementary treatments offered alongside standard IVF cycles lack robust clinical evidence — yet continue to be sold to patients who are often emotionally and financially vulnerable.

The Treatment in Question

IVF 'add-ons' are supplementary procedures, tests, or treatments offered by fertility clinics on top of standard IVF protocols, often for an additional fee. They are frequently marketed as ways to improve implantation rates or overall pregnancy success, though the scientific evidence underpinning many of them remains contested or limited.

Hormone-based add-ons are among the most commonly offered, with clinics suggesting they may improve uterine receptivity or support embryo implantation. However, the latest research indicates that at least one such treatment provides no statistically significant benefit to patients undergoing IVF.

Broader Concerns About Fertility Add-Ons

Fertility specialists and patient advocates have for some time flagged concerns about the add-on industry. Regulatory bodies in several countries, including the UK's Human Fertilisation and Embryology Authority (HFEA), have introduced traffic-light rating systems to help patients assess the evidence base behind offered treatments. Many popular add-ons have received red or amber ratings, meaning evidence of benefit is either absent or inconclusive.

Critics argue that fertility clinics have a financial incentive to offer add-ons, and that patients — often desperate after failed cycles — may be unlikely to question or decline treatments presented as beneficial by their treating doctors.

The cost of IVF in Australia is already substantial, with a single cycle typically ranging from $8,000 to over $10,000 out of pocket after Medicare rebates. Add-on treatments can push that figure significantly higher.

Calls for Greater Transparency

Researchers and patient advocates are calling for greater transparency from fertility clinics about the evidence — or lack thereof — supporting the treatments they offer. They argue that informed consent requires clinics to clearly communicate when a treatment is experimental or when evidence of benefit is weak.

The findings are likely to intensify calls for stronger regulatory oversight of the IVF add-on market in Australia, where clinics are not currently required to meet a specific evidence threshold before offering supplementary treatments to patients.

For patients navigating an already emotionally fraught process, experts recommend asking clinics for the specific evidence base behind any recommended add-on treatment, and seeking a second opinion where possible.

§

Analysis

Why This Matters

  • Millions of people undergo IVF globally each year, and many will be offered add-on treatments that carry additional costs — this research empowers patients to ask harder questions before agreeing to unproven extras.
  • The findings highlight a potential systemic issue in the fertility industry, where financial incentives may not always align with patient welfare or evidence-based medicine.
  • Regulatory bodies in Australia and internationally may face increased pressure to introduce stricter standards for what clinics can offer and how they must communicate risk and evidence to patients.

Background

IVF has been available since the late 1970s, with Australia playing a pioneering role — the world's third IVF baby was born in Melbourne in 1980. Over the decades, success rates have improved substantially through advances in laboratory techniques, embryo selection, and hormonal protocols.

However, as the industry has grown into a multi-billion dollar global market, so too has the proliferation of supplementary treatments. The UK's HFEA began formally reviewing and rating IVF add-ons in 2017, finding that the majority lacked sufficient evidence to be recommended. Australia has not introduced an equivalent national rating system, leaving patients reliant on individual clinic transparency.

Concerns about add-ons are not new — academic journals including Human Reproduction and The BMJ have published critical analyses over the past decade — but uptake of unproven treatments has continued, partly driven by patient demand and partly by clinic marketing.

Key Perspectives

Fertility Researchers: Argue that treatments should only be offered when there is robust, peer-reviewed evidence of benefit, and that the current environment places too much burden on patients to identify unproven options. Fertility Clinics: Many argue that add-ons are offered in good faith based on emerging or preliminary evidence, and that patients have a right to choose additional treatments even when the evidence base is still developing. Critics/Patient Advocates: Warn that emotionally vulnerable patients undergoing IVF are poorly positioned to critically evaluate clinical claims, and that the industry's commercial incentives create a structural conflict of interest that regulation must address.

What to Watch

  • Whether the Australian government or the Reproductive Technology Accreditation Committee (RTAC) moves to introduce clearer evidence standards for IVF add-ons following this research.
  • Publication of the full study findings, which may specify the hormone treatment involved and the scale of the clinical trial — details that will determine how broadly the conclusions can be applied.
  • Responses from major Australian IVF providers, several of which are listed companies with commercial interests in add-on offerings.

Sources

newspaper

Zotpaper

Articles published under the Zotpaper byline are synthesized from multiple source publications by our AI editor and reviewed by our editorial process. Each story combines reporting from credible outlets to give readers a balanced, comprehensive view.

Editorial ProcessSubscribe